{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:32Z","timestamp":1791216452150,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.chest.2020.08.2080","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T16:28:54Z","timestamp":1598977734000},"page":"673-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Tanja","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Assayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2020.08.2080_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2020.08.2080_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.chest.2020.08.2080_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2020.08.2080_bib4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.chest.2020.08.2080_bib6","first-page":"462","article-title":"The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax","volume":"66","author":"Navaratnam","year":"2011"},{"issue":"4","key":"10.1016\/j.chest.2020.08.2080_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2020.08.2080_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S2213-2600(17)30219-9","article-title":"Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?","volume":"5","author":"Johannson","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2020.08.2080_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1183\/09031936.00050911","article-title":"Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"39","author":"Lee","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2020.08.2080_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/thoraxjnl-2018-212102","article-title":"Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis","volume":"74","author":"Dutta","year":"2019","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.chest.2020.08.2080_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2020.08.2080_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2020.08.2080_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00376-2018","article-title":"The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies","volume":"51","author":"Tran","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.chest.2020.08.2080_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.chest.2020.08.2080_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2020.08.2080_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.chest.2020.08.2080_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1541-0420.2005.00356.x","article-title":"Propensity score matching with time-dependent covariates","volume":"61","author":"Lu","year":"2005","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pst.290","article-title":"Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods","volume":"7","author":"Matsuyama","year":"2008","journal-title":"Pharm Stat"},{"key":"10.1016\/j.chest.2020.08.2080_bib23","first-page":"A5710","article-title":"Proton pump inhibitors inhibit DDAH and improve survival in idiopathic pulmonary fibrosis","volume":"187","author":"Ho","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2020.08.2080_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-015-0614-x","article-title":"Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis","volume":"13","author":"Ghebremariam","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.5056\/jnm15192","article-title":"Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis","volume":"22","author":"Lee","year":"2016","journal-title":"J\u00a0Neurogastroenterol Motil"},{"issue":"3","key":"10.1016\/j.chest.2020.08.2080_bib26","first-page":"5805","article-title":"Chronic use of anti-reflux therapy improves survival of patients with pulmonary fibrosis","volume":"10","author":"Liu","year":"2017","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"10.1016\/j.chest.2020.08.2080_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2020.08.2080_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000468546","article-title":"Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone","volume":"93","author":"Kreuter","year":"2017","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.chest.2020.08.2080_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/resp.12781","article-title":"Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis: a population-based longitudinal study","volume":"21","author":"Ekstrom","year":"2016","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.chest.2020.08.2080_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12890-019-0846-2","article-title":"Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry","volume":"19","author":"Jo","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"5","key":"10.1016\/j.chest.2020.08.2080_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/aje\/kwq385","article-title":"Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias","volume":"173","author":"Howe","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.chest.2020.08.2080_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.chest.2020.08.2080_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.chest.2020.08.2080_bib34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.chest.2020.08.2080_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1742-1241.2012.02973.x","article-title":"Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care","volume":"66","author":"Ahrens","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.chest.2020.08.2080_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A\u00a0multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2020.08.2080_bib37","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220343105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220343105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:29:27Z","timestamp":1757924967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220343105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0012369220343105"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.08.2080","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.08.2080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}